Your browser is no longer supported. Please, upgrade your browser.
Settings
INMB [NASD]
INmune Bio, Inc.
Index- P/E- EPS (ttm)-0.99 Insider Own40.59% Shs Outstand14.32M Perf Week-8.51%
Market Cap142.89M Forward P/E- EPS next Y-2.26 Insider Trans0.00% Shs Float7.39M Perf Month-9.19%
Income-12.10M PEG- EPS next Q-0.33 Inst Own10.50% Short Float10.76% Perf Quarter-51.08%
Sales0.01M P/S13089.57 EPS this Y-35.00% Inst Trans0.39% Short Ratio4.40 Perf Half Y17.55%
Book/sh4.44 P/B2.20 EPS next Y-57.60% ROA- Target Price- Perf Year82.46%
Cash/sh3.10 P/C3.15 EPS next 5Y- ROE- 52W Range4.50 - 29.99 Perf YTD-43.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.39% Beta-
Dividend %- Quick Ratio22.40 Sales past 5Y- Gross Margin- 52W Low117.33% ATR1.03
Employees5 Current Ratio22.40 Sales Q/Q- Oper. Margin- RSI (14)38.00 Volatility9.61% 10.35%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.96 Prev Close9.29
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume180.84K Price9.78
Recom1.70 SMA20-14.16% SMA50-21.06% SMA200-22.03% Volume173,099 Change5.27%
Apr-21-21Initiated B. Riley Securities Buy $29
Jan-22-21Reiterated Maxim Group Buy $16 → $32
Sep-01-20Initiated BTIG Research Buy $23
Jul-15-20Reiterated H.C. Wainwright Buy $7 → $20
May-06-21 04:01AM  
May-05-21 04:15PM  
02:45PM  
Apr-28-21 09:00AM  
Apr-26-21 09:00AM  
04:16AM  
Mar-22-21 09:00AM  
Mar-08-21 09:00AM  
Mar-05-21 07:30PM  
Mar-04-21 04:15PM  
02:30PM  
Feb-25-21 09:00AM  
Jan-25-21 01:50AM  
Jan-21-21 03:53PM  
08:05AM  
07:00AM  
Jan-13-21 08:00AM  
Nov-27-20 10:59AM  
Nov-17-20 10:33AM  
Nov-09-20 07:00AM  
Nov-05-20 04:00PM  
Oct-29-20 08:30AM  
Oct-26-20 07:51AM  
Oct-05-20 09:00AM  
Sep-23-20 06:00AM  
Sep-16-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-13-20 09:00AM  
Aug-05-20 04:01PM  
Aug-03-20 07:00AM  
Jul-31-20 07:00AM  
Jul-27-20 07:00AM  
Jul-20-20 04:57PM  
01:07PM  
Jul-16-20 09:15AM  
Jul-15-20 04:10PM  
Jul-14-20 04:16PM  
08:04AM  
Jul-13-20 04:16PM  
Jul-09-20 09:00AM  
Jun-24-20 05:21AM  
Jun-11-20 09:00AM  
May-19-20 09:00AM  
May-14-20 09:00AM  
May-11-20 09:00AM  
May-06-20 04:20PM  
Apr-28-20 09:00AM  
08:09AM  
Apr-23-20 09:00AM  
Apr-22-20 10:55AM  
09:00AM  
Apr-20-20 09:00AM  
Mar-16-20 05:35AM  
Mar-11-20 09:00AM  
Mar-05-20 09:00AM  
Feb-27-20 09:00AM  
Feb-10-20 09:08AM  
Jan-29-20 08:25AM  
Jan-02-20 09:00AM  
Dec-17-19 09:00AM  
Dec-02-19 09:00AM  
Nov-26-19 06:00AM  
Nov-25-19 08:05AM  
Nov-19-19 09:00AM  
Nov-08-19 04:00PM  
Oct-21-19 03:00PM  
10:42AM  
Oct-17-19 09:00AM  
Oct-08-19 09:00AM  
Sep-24-19 10:20AM  
Sep-23-19 09:03AM  
Sep-20-19 10:02AM  
Sep-17-19 09:05AM  
Sep-12-19 08:30AM  
Sep-05-19 08:33AM  
Sep-04-19 09:06AM  
Aug-21-19 02:25PM  
10:30AM  
Aug-13-19 07:25AM  
Aug-12-19 09:01AM  
Aug-08-19 08:30AM  
Aug-06-19 03:40PM  
Aug-05-19 09:01AM  
Aug-01-19 09:01AM  
Jul-25-19 09:01AM  
Jul-03-19 09:01AM  
Jun-27-19 09:03AM  
Jun-11-19 08:30AM  
Jun-10-19 01:35PM  
Jun-04-19 04:45PM  
May-28-19 09:03AM  
May-22-19 10:00AM  
May-16-19 09:04AM  
May-15-19 09:03AM  
May-07-19 11:28AM  
08:01AM  
Apr-17-19 09:00AM  
Apr-15-19 11:15AM  
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.